Evidence map›Paper›PMID 40583992›Full record

ArticleJAC-antimicrobial resistance2025

Characterisation of

Anggia Prasetyoputri, Miranda E Pitt, Minh Duc Cao, Soumya Ramu, Angela Kavanagh, Alysha G Elliott, Devika Ganesamoorthy, Ian R Monk, Timothy P Stinear, Matthew A Cooper and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anggia PrasetyoputriCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Miranda E PittCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Minh Duc CaoCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0003-4079-2383
Soumya RamuCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Angela KavanaghCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Alysha G ElliottCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Devika GanesamoorthyCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Ian R MonkDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Timothy P StinearDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Matthew A CooperCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Lachlan J M CoinCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0002-4300-455X
Mark A T BlaskovichCentre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.ORCID https://orcid.org/0000-0001-9447-2292

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives: The increasing occurrence of MRSA clinical isolates harbouring reduced susceptibility to mainstay antibiotics has escalated the use of second and last line antibiotics. Hence, it is critical to evaluate the likelihood of MRSA developing clinical resistance to these antibiotics. Our study sought to characterize the development of resistance to vancomycin (VAN), daptomycin (DAP) and linezolid (LZD) in MRSA ATCC 43300 Methods: MRSA was exposed to increasing concentrations of VAN, DAP and LZD for 20 days, with eight replicates for each antibiotic conducted in parallel. The resulting day 20 (D20) isolates were subjected to antimicrobial susceptibility testing, whole genome sequencing, autolysis assays, and growth curves to determine bacterial fitness. Results: Exposure to VAN or LZD for 20 days resulted in a subtle 2-fold increase in the MIC, whereas DAP exposure yielded DAP-non-susceptible isolates with up to 16-fold MIC increase. The MIC increase was accompanied by variable changes in relative fitness and reduced resistance to autolysis in some isolates. D20 isolates harboured mutations in genes commonly associated with resistance to the respective antibiotics (e.g. Conclusions:

Identifiers

PMID40583992
PMCPMC12205958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.